nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2004-8-3-7-14nefr-844Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEПРЕВЕНТИВНЫЙ ПОДХОД В СОВРЕМЕННОЙ НЕФРОЛОГИИPREVENTIVE APPROACH IN NEPHROLOGYСмирновА. В.SmirnovA. V.КаюковИ. Г.KayukovI. G.ЕсаянА. М.EssaianA. M.ДобронравовВ. А.DobronravovV. A.КучерА. Г.KucherA. G.ТугушеваФ. А.TugushevaF. A.Научно-исследовательский институт нефрологии, Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаRussian Federation20041003200483714Copyright © Смирнов А.В., Каюков И.Г., Есаян А.М., Добронравов В.А., Кучер А.Г., Тугушева Ф.А., 20042004Смирнов А.В., Каюков И.Г., Есаян А.М., Добронравов В.А., Кучер А.Г., Тугушева Ф.А.Smirnov A.V., Kayukov I.G., Essaian A.M., Dobronravov V.A., Kucher A.G., Tugusheva F.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/844
Превентивный подход в современной нефрологии.
Preventive approach in nephrology.
нефрологияпревентивный подходхроническая болезнь почекnephrologypreventive approachchronic kidney diseaseReferencesLocatelli F, Del Vecchio L, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 2002; 17[Suppl 11]: 27Locatelli F, Del Vecchio L, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 2002; 17[Suppl 11]: 27Norris K, Vaughn C. The role of reninangiotensin aldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1(1): 5163Norris K, Vaughn C. The role of reninangiotensin aldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1(1): 5163Goumenos DS, Kalliakmani P, Tsakas S et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004; 61(1):1724Goumenos DS, Kalliakmani P, Tsakas S et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004; 61(1):1724Есаян АМ. Тканевая ренинангиотензиновая система почки. Новая стратегия нефропротекции. Нефрология 2002; 6(3): 816Есаян АМ. Тканевая ренинангиотензиновая система почки. Новая стратегия нефропротекции. Нефрология 2002; 6(3): 816Каюков ИГ, Есаян АМ, Кучер АГ, Ермаков ЮА. Роль функционально-гемодинамических механизмов в прогрессировании хронического гломерулонефрита. Нефрология 1998; 2(1): 713Каюков ИГ, Есаян АМ, Кучер АГ, Ермаков ЮА. Роль функционально-гемодинамических механизмов в прогрессировании хронического гломерулонефрита. Нефрология 1998; 2(1): 713Смирнов АВ. Дислипопротеидемии и проблемы не фропротекции. Нефрология 2002; 6(2): 814Смирнов АВ. Дислипопротеидемии и проблемы не фропротекции. Нефрология 2002; 6(2): 814Рентц Дун Б, Андерсон Ш, Бреннер Б. Гемодинамические основы прогрессирования почечных болезней. Современная нефрология. II международный нефрологический семинар. М., 1997; 162172Рентц Дун Б, Андерсон Ш, Бреннер Б. Гемодинамические основы прогрессирования почечных болезней. Современная нефрология. II международный нефрологический семинар. М., 1997; 162172Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 1117Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 1117Burgess ED, Carides GW, Gerth WC et al. Losartan reduces the costs associated with nephropathy and endstage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from Canadian perspective. Can J Cardiol 2004; 20(6): 613618Burgess ED, Carides GW, Gerth WC et al. Losartan reduces the costs associated with nephropathy and endstage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from Canadian perspective. Can J Cardiol 2004; 20(6): 613618Brenner BM, Cooper ME, De Zeew D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861 869Brenner BM, Cooper ME, De Zeew D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861 869Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003; 25(12): 30443064Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003; 25(12): 30443064Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay endstage renal disease in nondiabetic adults with chronic renal failure. Nephrol Dial Transplant 2000; 15: 19861992Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay endstage renal disease in nondiabetic adults with chronic renal failure. Nephrol Dial Transplant 2000; 15: 19861992Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoethin in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250256Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoethin in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250256Jafar TH, Schmid CH, Landa M et al. Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease. A metaanalysis of patientlevel data. Ann Intern Med 2001; 135: 7387Jafar TH, Schmid CH, Landa M et al. Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease. A metaanalysis of patientlevel data. Ann Intern Med 2001; 135: 7387Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851860Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851860Locatelli F, Del Vecchio L. How long can dialysis be postponed by low protein diet and ACE ihibitors? Nephrol Dial Transplant 1999; 13601364Locatelli F, Del Vecchio L. How long can dialysis be postponed by low protein diet and ACE ihibitors? Nephrol Dial Transplant 1999; 13601364Locatelli F, Del Vecchio L, D’Amico M, Andrulli S. Is it the agent or the pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13 [Suppl. 3]: S196S201Locatelli F, Del Vecchio L, D’Amico M, Andrulli S. Is it the agent or the pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13 [Suppl. 3]: S196S201Portoles J, Torralbo A, Martin P et al. Cardiovascular effect recombinant human erythropoetin in predialysis patients. Am J Kidney Dis 1997; 29: 541548Portoles J, Torralbo A, Martin P et al. Cardiovascular effect recombinant human erythropoetin in predialysis patients. Am J Kidney Dis 1997; 29: 541548Anonymous. Part 1. Executive summary. Am J Kidney Dis 2002; 39 [Suppl 1]: S17S31Anonymous. Part 1. Executive summary. Am J Kidney Dis 2002; 39 [Suppl 1]: S17S31Добронравов ВА, Царькова ОВ. Блокаторы кальциевых каналов в нефропротекции. Нефрология 2004; 8(1): 721Добронравов ВА, Царькова ОВ. Блокаторы кальциевых каналов в нефропротекции. Нефрология 2004; 8(1): 721Mann JF, Gerstein HC, Pogue J et al. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2003; 2(3): 157162Mann JF, Gerstein HC, Pogue J et al. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2003; 2(3): 157162Keith DS, Nichols GA, Gullion CM et al. Longitudinal followup study outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164(6): 659653Keith DS, Nichols GA, Gullion CM et al. Longitudinal followup study outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164(6): 659653Ravani P, Marinangeli G, Tancredi M, Malberti F. Multidisciplinary chronic kidney disease management improves survival on dialysis. J Nephrol 2003; 16(6): 870877Ravani P, Marinangeli G, Tancredi M, Malberti F. Multidisciplinary chronic kidney disease management improves survival on dialysis. J Nephrol 2003; 16(6): 870877Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 3141Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 3141Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction indication. Modification of Diet in Renal Disease Study Group . Ann Intern Med 1999; 130(6): 471Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction indication. Modification of Diet in Renal Disease Study Group . Ann Intern Med 1999; 130(6): 471Frequently asked questions about GFR estimation. http://www.kidney.orgFrequently asked questions about GFR estimation. http://www.kidney.orgСмирнов АВ. Хроническая болезнь почек или хроническое заболевание почек? Нефрология 2004; 8(1): 101102Смирнов АВ. Хроническая болезнь почек или хроническое заболевание почек? Нефрология 2004; 8(1): 101102
The authors declare that there are no conflicts of interest present.